As part of its Speaking Out series, Patrick Wagner, MD, discusses eligibility and considerations for oncolytic viral therapies.
Videos
Stacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.
Yucai Wang, MD, PhD, discusses the rationale, methods, and design of a study evaluating the efficacy of pembrolizumab when given as both a monotherapy and in combination with B-cell receptor inhibitors for Richter transformation of CLL.
Downstream impacts of ruxolitinib in polycythemia vera treatment are illustrated by a panel of medical experts.
Tarah Ballinger, MD, discusses findings from the phase 2 EAZ171 study of taxane-induced peripheral neuropathy in Black patients with breast cancer.
Rebecca Shatsky, MD, discusses findings from the ISPY2.2 trial presented at the 2024 ASCO Annual Meeting.
Dr. Bose discusses the potential role of other treatment modalities, such as ruxolitinib combination therapies or novel agents, in managing this patient's myelofibrosis and anemia, including the emerging treatment options that may be relevant to this case.
Suresh Ramalingam, MD, principal investigator of the phase 3 LAURA trial, explains the study's evaluation of osimertinib in EGFR-mutated non-small cell lung cancer.
Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.
Peter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.
Puneeth Indurlal, MD, MS, discusses the implications of assessing for patients' health-related social needs during the course of cancer treatment at the 2024 ASCO Annual Meeting.
Vikram Narayan, MD, discusses the significance of the 5-year overall survival and cystectomy-free survival rates of nadofaragene firadenovec-vncg in treating patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Dr. Bose discusses the potential adverse effects associated with ruxolitinib therapy and how they should be managed in this patient, with a focus on addressing the risk of anemia and other hematologic adverse effects.
Halle Moore, MD, discusses key takeaways from a study on young patients with breast cancer carrying BRCA mutations presented at the 2024 ASCO Annual Meeting.
Lori J. Wirth, MD, discusses some of the unmet needs that exist in the thyroid cancer space following the FDA approval for lenvatinib for radioactive iodine-refractory differentiated thyroid cancer.
As part of its Speaking Out video series, Howard D. Edington, MD, explores how oncolytic viruses are revolutionizing personalized cancer therapy, the challenges of interpreting vast genetic data, and the exciting potential of these targeted therapies.
Dr Bose drives a discussion surrounding the treatment of advanced polycythemia vera.
The panel of experts dissect findings around breaking JAK inhibitor data in myelofibrosis treatment.
Guillermo Garcia-Manero, MD, discusses the design and outcomes of the phase 3 COMMANDS trial in patients with low-risk myelodysplastic syndromes.
Doris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.
Jose Lutzky, MD, discusses clinical trials investigating novel therapies for melanoma.
Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the specific patient subgroups for whom autologous transplant remains the best course of action for.
The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.
Jose Lutzky, MD, discusses the innovative tumor-inflitrating lymphocyte therapy for the treatment of relapsed or refractory melanoma.
Rahul Banerjee, MD, FACP, physician-researcher at Fred Hutch Cancer Center in Seattle, WA, discusses the potential links between CAR T-cell therapy and secondary T-cell malignancies.
Targeted Oncology spoke with Howard D. Edington, MD, about how experts are addressing the potential of resistance challenges with oncolytic viruses as part of its Speaking Out video series.
Prithviraj Bose, MD, introduces study designs for trials focusing on JAK inhibitor utilization in patients receiving treatment for myelofibrosis.
Medical experts discuss strategies to navigate a complex patient scenario pertaining to previous refusal of ASCT.